Equities

1nkemia IUCT Group SA

1nkemia IUCT Group SA

Actions
  • Price (EUR)0.31
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Inkemia IUCT Group SA is a Spain-based company primarily specialized in the biotechnological sector. The Company provides products and services for chemical, pharmaceutical, biopharmaceutical, life science and related industry. The Company’s activity is related to the generation, promotion, development and sale of products and services. The Company transforms its knowledge and know-how into a pipeline of products, processes, services and technological platforms. Its solutions are specialized, integrated and protected by patents. The main areas of expertise are related to drugs development, industrial biotechnology and green chemistry. The Company has a number of subsidiaries, including IUCT SA and IUCT Empren SL.

  • Revenue in EUR (TTM)5.46m
  • Net income in EUR-24.32m
  • Incorporated2010
  • Employees45.00
  • Location
    1nkemia IUCT Group SAC/ Alvarez de Castro, 63MOLLET DEL VALLES 08100SpainESP
  • Phone+34 935793432
  • Fax+34 935705745
  • Websitehttps://www.inkemia.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Acrux Ltd4.96m-3.55m8.02m43.00--3.99--1.62-0.02-0.020.0280.01130.728--2.61---52.14-45.05-71.89-54.0451.14---71.62-114.01----0.5307---32.118.91-659.16---6.20--
Coeptis Therapeutics Holdings Inc0.00-15.33m8.02m5.00---------0.5143-0.51430.00-0.01110.00----0.00-284.35-37.29-709.12-38.23------------1.22------43.40------
Laboratorio Farmaceutico Erfo SpA5.71m404.60k8.32m39.0019.541.057.451.460.04730.04730.66650.88130.53943.098.78173,045.503.8313.404.6916.7640.5451.817.1121.011.5123.760.0501--24.068.62-22.66-13.88----
1nkemia IUCT Group SA5.46m-24.32m8.36m45.00------1.53-0.9012-0.90120.2024-0.28970.2021.312.14---90.11-31.58-171.35-71.3791.46102.07-445.97-198.820.2643.181.74--1.68-40.6795.72---73.14--
Oncozenge AB0.00-1.02m8.42m----6.86-----1.01-1.010.001.210.00-------55.08---59.44-------------2,944.500.00------65.91------
Organon Pharma Indonesia Tbk PT165.44m6.36m8.55m187.00----0.99470.051729,488.8029,488.80767,296.60283,451.201.685.894.9813,880,730,000.006.4711.419.8015.867.4912.573.846.781.3543.760.004--17.454.497.398.11-14.93--
Cytophage Technologies Ltd0.00-5.27m8.56m----2.40-----0.3779-0.37790.000.0978----------------------------0.2374-------25.88------
Willow Biosciences Inc1.94m-5.21m8.77m19.00--66.56--4.52-0.0604-0.06040.02220.00140.4901--6.33151,000.00-131.79---193.14-------268.91--0.756--0.9002--42.75--12.05------
Data as of Nov 14 2024. Currency figures normalised to 1nkemia IUCT Group SA's reporting currency: Euro EUR
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.